AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.83
+1.32%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.83
From 52W high−48.87%
Volume3.33M
Market cap$480.71M
P/E (TTM)—
P/S (TTM)8.9x
Div yield—
Key dataOct 19, 2026
Open
$3.83
From 52W high
−48.87%
Volume
3.33M
Market cap
$480.71M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.2x
P/E (TTM)
—
RSI (14)
28.1
MomentumView details →
1D Return
+1.32%
YTD Return
−41.10%
SummaryUpdated Jun 1, 2026
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a specialty pharmaceutical company founded in 2004 and headquartered in Warren, New Jersey. The company went public in July 2018 and focuses on developing and commercializing innovative drug delivery technologies, particularly through its proprietary oral soluble film platform. Aquestive has evolved from a contract manufacturing organization into a fully integrated pharmaceutical company with both commercial products and a robust pipeline of proprietary drug candidates targeting various therapeutic areas including epilepsy, anaphylaxis, ADHD, and rare diseases.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration accepted Aquestive Therapeutics’ resubmitted NDA for Anaphylm as complete and assigned a PDUFA goal date of March 16, 2027.5d agoAquestive Therapeutics agreed to serve as Eton Pharmaceuticals' exclusive manufacturer and supplier of the product under a supply agreement with an initial 20-year term.6d agoEton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film.6d ago